Currently, in the United States, there are only a small number of prescription weight-loss drugs (sometimes called anti-obesity drugs) that have been approved for marketing in this country. One of these is Alli.
This does not mean there aren’t other weight loss drugs out there; there are both prescription and non-prescription. However, other prescription drugs, of which Acomplia (the European Union, or EU, brand name for rimonabant) is one, are available. This drug has not been approved for marketing in the U.S.
Although it has not been approved for U.S. marketing, rimonabant already has a U.S. brand name. Here it is known as Zimulti.Rimonabant works by blocking certain receptors, known as CB1 receptors, found in the brain and other organs that play a role in metabolizing glucose and lipids (or fats). These organs are known as “peripheral organs” and include adipose tissue, the liver, the gastrointestinal tract (not just the intestines, but literally from the esophagus to the rectum), and muscle.
In addition, Acomplia—remember this is the EU brand name for rimonabant — also has the ability to turn off the circuits in the brain that make marijuana smokers feel hungry after having done so. In other words, people who take this drug don’t get the “munchies” after smoking marijuana. For the regular person, this means that you won’t feel the need to snack in between meals.
Although it has not been approved for use in the U.S., Acomplia is available for purchase from drug stores online. When purchasing drugs online, there are risks involved including purchasing a product that claims to include the active ingredient (in this case, rimonabant) but does not, so if you decide to purchase online, be sure to buy from a trusted online pharmacy that is known for its quality and respectability. This will reduce any risks and you will be sure to receive a quality product.
